Zeffix

RSS

lamivudine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Zeffix. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zeffix.

This EPAR was last updated on 19/07/2022

Authorisation details

Product details
Name
Zeffix
Agency product number
EMEA/H/C/000242
Active substance
lamivudine
International non-proprietary name (INN) or common name
lamivudine
Therapeutic area (MeSH)
Hepatitis B, Chronic
Anatomical therapeutic chemical (ATC) code
J05AF05
Publication details
Marketing-authorisation holder
GlaxoSmithKline (Ireland) Limited
Revision
29
Date of issue of marketing authorisation valid throughout the European Union
29/07/1999
Contact address

12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland

Product information

18/07/2022 Zeffix - EMEA/H/C/000242 - IAIN/0084

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Zeffix is indicated for the treatment of chronic hepatitis B in adults with:

  • compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate;
  • decompensated liver disease in combination with a second agent without cross-resistance to lamivudine.

Assessment history

How useful was this page?

Add your rating
Average
1 rating